Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1212-1218

  Rubenstein, Marvin ^a,b,c   Hollowell, Courtney M P ^b   Guinan, Patrick ^a,b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b Jr Hospital of Cook County   (United States)

^c RUSH UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA ANTIGEN; LIPOFECTIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2;

ANTIGEN EXPRESSION; ARTICLE; BINDING SITE; CELL DENSITY; CELL GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; RNA EXTRACTION; SEQUENCE HOMOLOGY;

ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79951775310     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9361-2     Document Type: Article

References (18)

1. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA. 1988;85:5011-5.
2. Felsenfeld G, Miles HT. Formation of a three-stranded polynucleotide molecule. J Am Chem Soc. 1957;79:2023-4.
3. Durland RH, Kessler DJ, Hogan M. Antiparallel triplex formation at physiological pH. In: Wickstrom E, editor. Prospects for antisense nucleic acid therapy of cancer and AIDS. New York: Wiley-Liss; 1991. p. 219-26.
4. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol. 2006;28:515-8. (Pubitemid 44885380)
5. Rubenstein M, Tsui P, Guinan P. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate cancer. Med Oncol. 2007;24:372-8. (Pubitemid 350135928)
6. Rubenstein M, Tsui P, Guinan P. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel. Med Oncol. 2009;26:124-30.
7. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses. 2005;65:905-7.
8. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. Med Oncol. 2007;24:189-96. (Pubitemid 350135970)
9. Rubenstein M, Tsui P, Guinan P. Treatment of MCF-7 breast cancer cells employing mono-and bispecific antisense oligonucleotides having binding specificity towards proteins associated with autocrine regulated growth and bcl-2. Med Oncol. 2008;25:182-6.
10. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B, Gleave M. Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and bcl-xL expression induce apoptosis and enhance chemosensitivity in human and rogen-independent prostate cancer cells. Proceedings AACR. 2004;45: Abstract # 2930.
11. Takahara K, Muramaki M, Li D, Cox ME, Gleave ME. Insulinlike growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation. J Urol. 2009;181:184a.
12. Lubaroff DM, et al. Outcomes from a phase I trial of an adenovirus/PSA vaccine for prostate cancer. J Urol. 2008;179(suppl): 184. Abstract 526.
13. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induced HLA-DR expression on cultured human keratinocytes. J Invest Derm. 1984;83:88-90. (Pubitemid 14054909)
14. Msujimoto M, Yip YK, Vilcek J. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. J Immunol. 1986;136:2441-4. (Pubitemid 16136820)
15. Rubenstein M, Mirochnik Y, Chow P, Guinan P. Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol. 1996;62:194-200. (Pubitemid 26231490)
16. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Med Hypothese. 2006;67:1375-80. (Pubitemid 44442657)
17. Lee B-S, Fujita M, Ljubimova JY, Holler E. Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid. Proceedings AACR. 2004;45:647a.
18. Santhakumaran L, Thomas T, Thomas TJ. Nanoparticle formation in an antisense oligonucleotide by polyproplin-imine dendrimers: facilitation of cellular uptake and intracellular stability. Proceedings AACR. 2004;45:2938a.